BioSpace News Archive

Policy

China’s First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. announces that the New Drug Application for IBI351 has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China and granted Priority Review designation[1], for the treatment of patients with advanced non-small cell lung cancer harboring KRAS G12C mutation who have received at least one systemic therapy.

November 23, 2023
·
9 min read
Deals

Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang

Broncus is pleased to announce that, on November 23 2023 Broncus Hangzhou has entered into the Equity Transfer Agreement with the shareholders of the Hangzhou Jingliang, to acquire 100% equity interest in it.

November 23, 2023
·
2 min read
Policy

Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients

Everest Medicines announced that China’s National Medical Products Administration has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression.

November 23, 2023
·
9 min read